Caracterización clínica y bioquímica de la mujer con Síndrome de Ovario Poliquístico

Carlos Alfonso Builes, Ivonne Díaz, Jimmy Castañeda, Luis Ernesto Pérez

Resumen


El Síndrome de Ovario Poliquístico (SOP) tiene una prevalencia entre 4 y 8% en la población general joven (18 a 45 años de edad). Su diagnóstico se hace con la presencia de dos de los siguientes tres criterios: oligo-anovulación, anovulación, hiperandrogenismo clínico o asintomático y morfología poliquística del ovario al ultrasonido. En el estudio del SOP se deben descartar otras causas de hiperandrogenismo como hiperplasia adrenal congénita, síndrome de Cushing y tumores productores de andrógenos. Las pacientes con SOP tienen alto riesgo de desarrollar intolerancia a los carbohidratos, diabetes y síndrome metabólico, pero no existe evidencia clínica contundente que respalde en ellas una mayor incidencia de eventos isquémicos del miocardio, ni de cáncer endometrial.

Palabras clave


síndrome del ovario poliquístico; hirsutismo; hiperandrogenismo

Texto completo:

PDF

Referencias


Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.

Knochenhauer ES, Key TJ, Hahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.

Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin Endocrinol Metab 2000;85:2434-8.

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Endocrinol Metab 2004;89:2745-9.

Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol. (oxf) 1999;51:779-86.

Saleh AM, Khalil HS. Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2004;83:614-21.

Rotterdam ESHRE / ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.

Malcolm CE, Cumming DC. Does anovulation exist in eumenorrheic women?. Obstet Gynecol 2003;102:317-8.

Wild R, Vesely S, Beebe L, Whitsett T, Owen W. Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome. J. Clin Endocrinol Metab 2005;90:4112-4.

Ehrman D. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.

Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries-- a common finding in normal women. Lancet 1988;1:870-2.

Adams J, Taylor A, Crowley WF Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab 2004;89:4343-50.

Jonard S, Robert Y, Cardet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003;18:598-603.

Dewailly D. Nonclassic 21-hidroxilase deficiency. Semin Reprod Med 2002;20:243-8.

Moran C, Azziz R. 21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Semin Reprod Med 2003;21:295-300.

Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med 2003;138:980-91.

Growth Hormone Society: Pituitary Society. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 2004;89:3099-102.

Pérez LE. Síndrome de Ovario poliquístico. Patologías asociadas a hirsutismo. En: Pérez LE. Infertilidad y Endocrinología Reproductiva. 2a. ed. Bogotá, Colombia: Imprenta Hospital Militar; 2000. p. 152-61.

Schlechte J. Clinical practice. Prolactinoma. N Engl J Med 2003;349:2035-41.

Bayrak A, Saadat P, Mor E, Chong R, Paulson RJ, Sokol RZ. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril 2005;84:181-5.

Kalro BN. Impaired fertility caused by endocrine dysfunction in women. Endocrinol Metab Clin North Am 2003;32:573-92.

García J, Polanía D, Builes CA. Hiperplasia hipofisiaria secundaria a hipotiroidismo primario. Acta Med Colomb 2005;30:65-7.

Ozbey N, Sariyildiz E, Yilmaz L, Orthan Y, Sencer E, Molvalilar S. Primary hypothyroidism with hyperprolactinaemia and pituitary enlargement mimicking a pituitary macroadenoma. Int J Clin Pract 1997;51:409-11.

Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005;83:1327-32.

Padrón R, Sell J, Montejo L. Búsqueda de trastornos endocrinos en pacientes con falla ovárica prematura. Rev Cubana Endocrinol 2001;12:144-9.

The IDF consensus world wide definition of metabolic syndrome. 2005. http://www.IDF.org

Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 2004;191:713-7.

Isojarvi JL, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproato for epilepsy. N Engl J Med 1993;329:1383-8.

Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-8.

Norman RJ, Wu R, Stankiewicz M. Polycystic ovary syndrome. Med J Aust 2004;180:132-7.

Ibanez L, Polau N, de Zegher F. Ovarian hyperresponsiveness to follicle stimulating hormone in adolescent girl born small for gestational age. J Clin Endocrinol Metab 2000;85:2624-6.

Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001;86:2027-31.

Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.

Dunaif A, Segal KR, Futter weit W, Dobrjaosky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.

Apridonidze T, Essah P, Inorno M,. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-35.

Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long term follow up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600.

Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2.


comments powered by Disqus

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2016 Revista Colombiana de Obstetricia y Ginecología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN Impreso       0034-7434 

ISSN Electrónico   2463-0225

https://doi.org/10.18597/issn.0034-7434